Daniel Timmermann’s Post

There has been a whole host of trial readouts and new data for pulmonary fibrosis, especially as the ATS congress was just last week, and it feels like the IPF field is really on the edge of bringing new, more efficacious, therapeutics to the market for patients in need. Here's some of the recent news: - Vicore Pharma AB announced data from their Phase IIa trial and will kickstart their Phase IIb trial for buloxibutid - Ahmed Mousa and Professor Bertil E. Lindmark MD, PhD will be presenting at the IPF Summit - Pliant Therapeutics Bexotegrast has shown to reverse the signs of lung scariing, while improving lung function and easing cough - Gregory Cosgrove MD will be presenting at the IPF Summit - Aileron Therapeutics reported data from cohort one of the phase 1b trial - Brian Windsor will be presenting at the IPF Summit - GRI Bio, Inc. presented positive preclinical data demonstrating that the lead program reduces inflammatory and fibrotic drivers of IPF - Vipin Kumar (Chaturvedi) will be presenting at the IPF Summit With all the news in the space, why not join the community at a dedicated forum this August where you can discuss the drug development challenges for pulmonary fibrosis in-depth? The 8th IPF Summit (see full event guide here: https://ter.li/ipf) is the go-to venue for 150+ senior decision makers, academic KOLs, fibrosis experts and innovators to unite to discuss all things pulmonary fibrosis! From harnessing emerging biological understanding, to applying novel and evolving models, to assessing patient populations, this is your comprehensive and dedicated forum to propel innovative and efficacious pulmonary fibrosis therapeutics through phase 2 and beyond. Access the full event guide here: https://ter.li/ipf where you can see the full session details from 40+ expert speakers 2024 Event Partners: Qureight, Nordic Bioscience, FibroFind, Vitalograph, Imbio, Brainomix, MannKind Corporation, Fortrea, IPS Therapeutique (IPST), Strados Labs, Ionis Pharmaceuticals, Inc., Aragen Life Sciences I hope you can join the pulmonary fibrosis community at this year's IPF Summit! #ipf2024 #ipfsummit #pulmonaryfibrosis #fibrosis #lunghealth #respiratory #lung #drugdevelopment #idiopathicpulmonaryfibrosis

Happy to share portfolio update of our Innovation fund OMX Europe! MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002 MRM Health is a clinical-stage microbiome platform developing innovative therapeutics for inflammatory, CNS and metabolic diseases, based in Ghent (Belgium). MRM Health leverages its proprietary disruptive CORAL® technology platform to rationally design microbiome therapeutics, based on disease-focused specific combinations of 5 to 10 live gut bacteria, and to optimize them for faster onset-of-action and increased potency and robustness. The multi-center, open-label clinical trial in 14 acute Pouchitis patients met its objectives: ✅Excellent Safety ✅Excellent Tolerability ✅Effective Outcomes, including a 46% clinical remission rate and a 42% reduction in symptom scores at week 8. These new clinical results further enhance the positive clinical data previously reported with MH002 in the treatment of Ulcerative Colitis (UC). Based on the combined results from both clinical trials and recent positive feedback from regulatory authorities, the Company is in the position to initiate Phase 2/3 clinical trial in Ulcerative Colitis, to be combined with further trial in Pouchitis. 🚀 We congrat the MRM Health team for this achievement! Mérieux Equity Partners, through its fund OMX Europe with the support of Korys, has been a committed investor to the company since 2020. #MérieuxEquityPartners #MRMHealth #Innovation #Healthcare #ClinicalTrials #Pouchitis

MBTI's very own Priya Kumthekar, MD, Atique Ahmed, PhD, and Ditte Primdahl, MD, will be attending the 6th annual Glioblastoma Drug Development Summit. Dr. Kumthekar, MD, will host a roundtable on "Preparing for Clinical Trial: Designing a Framework of Communication for Optimal Patient Welfare & Sponsor Outcomes." Professor Ahmed, PhD, will host a workshop on "Optimizing and Evaluating Glioblastoma Models for Effective Drug Testing," and Dr. Primdahl, MD, will host a workshop on "Harnessing Tumor-Treating Fields to Modulate the Tumor Microenvironment in Glioblastoma." To learn more about each topic click the link below: https://lnkd.in/erpN6vvj

We are thrilled to announce that AC Immune and Takeda have won the #Deal of the Year (>€500M) at the European Lifestars Awards - Celebrating Life Science Leaders. This recognition highlights our transformative license and option agreement centered on ACI-24.060, our active immunotherapy candidate targeting toxic forms of amyloid beta in Alzheimer’s disease. Currently under evaluation in the ABATE Phase 1b/2 trial, ACI-24.060 has also received Fast Track designation from the U.S. FDA, emphasizing its potential to address this critical unmet medical need. This #partnership with Takeda embodies our commitment to pioneering precision prevention for neurodegenerative diseases. Thank you to our dedicated team at AC Immune and our partners at Takeda for making this possible. Together, we will reshape the future of #Alzheimer’s #treatment and #prevention. #Neurodegeneration #PrecisionMedicine #Award #Biotech #Biopharma

🌟 Who are going to be the winners on #socialmedia at #ESMOCongress?…have a look at what happened last year ;) 🔍 Key Hashtags: Online conversations spotlighted #lungcancer, #breastcancer, #prostatecancer, #bladdercancer, medical education and #immunotherapy as major areas of focus. 💬 Top Discussion Themes: Εfficacy, clinical trials, new data, safety and patient-related topics, in that order, had a notable presence. 👩⚕️ Leading Voices: #Physicians dominated the conversation, contributing to 79% of posts, followed by education-related content at 14% and media at 7%. 📈 Audience Sentiment: The overall sentiment was overwhelmingly positive, with ESMO 2023 praised for high quality presentations, networking opportunities, medical innovations and smooth event logistics. 🧠 Text Analytics: The key discussions concentrated on #Neoadjuvant and #Combination Therapies. #Lungcancer was the most discussed, followed by #colorectalcancer and #breastcancer. 🎯 👉 Get your copy of the full #ESMO23 report below (go to full screen mode and download a .pdf) or find the link in the comments 📥 American Society of Clinical Oncology (ASCO) ESMO - European Society for Medical Oncology AstraZeneca Bayer Pfizer Johnson & Johnson Novartis AbbVie Astellas Pharma Bristol Myers Squibb Daiichi Sankyo Europe GmbH Eli Lilly and Company GSK EMD Serono, Inc. MSD Roche Sanofi Servier Takeda Oncology #HealthcareConsulting #ESMO23 #ESMO24 #SocialListening #DigitalHealth #OncologyInsights #MedicalEducation #LucidQuest

💲 💉 Pioneering Alzheimer’s Care: Eisai and Biogen's New Dosing Strategy for Leqembi 💊 Alzheimer’s treatment is advancing, and I’m thrilled to share my latest project for Daily Dose Pharma that explores Eisai US and Biogen’s latest push for IV maintenance dosing of LEQEMBI® (lecanemab-irmb) HCP in the U.S. As Alzheimer's disease continues to impact millions of lives, Leqembi’s innovative approach offers new hope for early intervention and long-term care. Leqembi, a groundbreaking treatment for early Alzheimer’s, now aims to offer monthly IV and weekly subcutaneous dosing options, which will play a key role in maintaining effective drug levels and slowing disease progression. The implications for patient care are enormous, with clinical trials showing sustained clearance of harmful amyloid beta protofibrils. Working on this presentation gave me incredible insights into the future of Alzheimer’s treatment, as Leqembi looks poised to revolutionize patient management. With projected "$7.3bn in sales by 2030", this drug is set to be a major player in the market. Excited to dive deeper into this innovative dosing strategy and how it compares to previous treatments like Aduhelm. Curious about how Leqembi’s new dosing could change the future of Alzheimer’s care? Tune into Daily Dose Pharma to explore more! #AlzheimersTreatment #PharmaInnovation #Biogen #Leqembi #DailyDosePharma #FutureOfHealthcare

Our portfolio company, HAYA Therapeutics, is partnering with Eli Lilly and Company to discover new genome targets for obesity and related metabolic conditions, in a deal worth up to $1 billion. By leveraging HAYA’s proprietary RNA platform to target key mechanisms of metabolic diseases, the goal is to transform the treatment landscape for obesity and related metabolic conditions. This landmark collaboration positions HAYA as a leader in developing innovative treatments for chronic and age-related diseases. As HAYA’s largest & first institutional investor, we are excited to see this alignment with Apollo Health Ventures' investment strategy, which focuses on addressing these conditions at their roots, pushing the boundaries of medicine, and offering promising new therapies to patients worldwide. Read more about this multi-year agreement in their press release: https://lnkd.in/eGDSiHHd #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

🤩 Exciting times in Alzheimer’s treatment! 🌟 With recent FDA approvals like Aduhelm® and Leqembi®, 2024 is a pivotal "learning year" for advancements. Dr. Jeffrey Cummings, UNLV's expert, reveals a diverse pipeline of treatments, driven by biomarker inclusion and innovative strategies. In his latest report, Cummings unveils 164 active trials and 127 unique treatments, showcasing promising results, including disease-modifying therapies and repurposed agents. However, funding challenges persist, hindering progress. Yet, hope prevails as research continues, with potential FDA approval for donanemab on the horizon. The future holds promise for safer, more effective treatments, offering hope to millions affected by Alzheimer’s. 🔗 https://lnkd.in/ewtGK9bA #AlzheimersResearch #MedicalInnovation #ClinicalTrials

Data sharing and Alzheimer’s Disease—learn more about it at the panel below:

The FDA encouraged scientists and drug developers to use the alpha-synuclein seed amplification assay (αSyn-SAA) biomarker, discovered in 2023, for research and clinical trials in a “Letter of Support” issued late Summer 2024. The Letter of Support follows multi-stakeholder collaboration amongst The Michael J. Fox Foundation for Parkinson's Research and the Critical Path Institute, with both organizations supporting use of the biomarker for clinical trials and advancing new drugs for Parkinson’s disease. Because the tool can objectively detect early biology related to Parkinson’s and related diseases, including Dementia with Lewy Bodies, even before any symptoms emerge, trials using the biomarker are better positioned to test therapies that aim to delay or even prevent the onset of disease. The use of the tool also enables research toward tailored therapies to treat individuals at all stages of these diseases. “This FDA Letter of Support is a transformative moment for the field, promising to speed clinical trial design in Parkinson’s and related disorders,” said Diane Stephenson, PhD, executive director, CPP, C-Path. “The cross-collaboration among patients, researchers, clinicians, regulators and patient advocacy organizations demonstrates the critical role every player holds in moving today’s achievement forward. Now, we’re closer than ever to better treatments, and perhaps one day, preventing people from developing the symptoms of these diseases altogether.” Full details, here: https://lnkd.in/gqhuVqnW #CPath #MJFF #FDA #Parkinsons #PD #Biomarker #drugdevelopment #diseaseprevention #datasharing #globalhealth #collaboration